Download PDF
Z Gastroenterol 2003; 41(1): 36-42
DOI: 10.1055/s-2003-36666
Leitlinien der DGVS
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Remissionserhaltung

Maintaining a RemissionW. E. Fleig1
  • 1Klinik und Poliklinik Innere Medizin I, Universitätsklinikum Kröllwitz, Halle
Further Information

Publication History

Publication Date:
16 January 2003 (online)

Also available at
    Permissions and Reprints

Definitionen
Remission

Konsens

Die Remission des M. Crohn wird klinisch definiert. Kriterien für diese Definition sind fehlende klinische Zeichen und Symptome eines M. Crohn (Bauchschmerzen, Diarrhö, Fistelsekretion, andere intestinale und extraintestinale Symptome; C).

Erläuterung

Diese Definition nimmt eine Remission an, sobald Symptome und Zeichen der aktiven Erkrankung verschwunden sind. Während die Definition der chronisch aktiven Erkrankung (siehe dort) einen Verlauf von mindestens 6 Monaten unter adäquater Therapie fordert, ist offen, wie lange unter bzw. nach Akutphasentherapie Symptomfreiheit bestehen muss, um eine stabile klinische Remission annehmen und deshalb folgerichtig die Akutphasentherapie beenden zu können. Diese Unschärfe im Übergang vom ausklingenden akuten Schub zur Remission dürfte einige Wochen betragen. Prospektive Daten zu dieser Problematik existieren nicht.

Literatur

  • 1 Rutgeerts P, Geboes K, Vantrappen G. et al . Predictability of the postoperative course of Crohn’s disease.  Gastroenterology. 1990;  99 956-963 (III)
    Google Scholar
  • 2 Ludwig D, Wiener S, Bruning A. et al . Mesenteric blood flow is related to disease activity and risk of relapse in Crohn’s disease: a prospective follow-up study.  Am J Gastroenterol. 1999;  94 2942-2950 (III)
    Google Scholar
  • 3 Brignola C, Campieri M, Bazzocchi G. et al . A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease.  Gastroenterology. 1986;  91 1490-1494 (III)
    Google Scholar
  • 4 Brignola C, Iannone P, Belloli C. et al . Prediction of relapse in patients with Crohn’s disease in remission: a simplified index using laboratory tests, enhanced by clinical characteristics.  Eur J Gastroenterol Hepatol. 1994;  6 955-961 (III)
    Google Scholar
  • 5 Landi B, Anh T N, Cortot A. et al . Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives.  Gastroenterology. 1992;  102 1647-1653 (Ib)
    Google Scholar
  • 6 Silverstein M D, Loftus E V, Sandborn W J. et al . Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort.  Gastroenterology. 1999;  117 49-57 (IIb)
    Google Scholar
  • 7 Sutherland L R, Martin F, Bailey R J. et al . A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn’s disease.  Gastroenterology. 1997;  112 1069-1077 (Ib)
    Google Scholar
  • 8 Timmer A, Sutherland L R, Martin F. et al . Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease.  Gastroenterology. 1998;  114 1143-1150 (III)
    Google Scholar
  • 9 Holdstock G, Savage D, Harman J E. et al . Short report: Should patients with inflammatory bowel disease smoke?.  BMJ. 1984;  288 362 (III)
    Google Scholar
  • 10 Cottone M, Rosselli M, Orlando A. et al . Smoking habits and recurrence in Crohn’s disease.  Gastroenterology. 1994;  106 643-648 (III)
    Google Scholar
  • 11 Breuer-Katschinski B D, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn’s disease.  Eur J Gastroenterol Hepatol. 1996;  8 225-228 (III)
    Google Scholar
  • 12 Gendre J P, Mary J Y, Florent C. et al . Oral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: A multicenter placebo-controlled study.  Gastroenterology. 1993;  104 435-439 (Ib)
    Google Scholar
  • 13 Sachar D B, Subramani K, Mauer K. et al . Patterns of postoperative recurrence in fistulizing and stenotic Crohn’s disease. A retrospective cohort study of 71 patients.  J Clin Gastroenterol. 1996;  22 114-116 (III)
    Google Scholar
  • 14 Post S, Herfarth C, Böhm E. et al . The impact of disease pattern, surgical management and individual surgeons on the risk for relaparotomy for recurrent Crohn’s disease.  Ann Surg. 1996;  223 253-260 (III)
    Google Scholar
  • 15 Munoz-Juarez M, Yamamoto T, Wolff B G. et al . Wide-lumen stapled anastomosis vs. conventional end-to-end anastomosis in the treatment of Crohn’s disease.  Dis Colon Rectum. 2001;  44 20-25 (Ib)
    Google Scholar
  • 16 Hashemi M, Novell J R, Lewis A A. Side-to-side stapled anastomosis may delay recurrence in Crohn’s disease.  Dis Colon Rectum. 1998;  41 1293-1296 (IIa)
    Google Scholar
  • 17 Poggioli G, Stocchi L, Laureti S. et al . Conservative surgical management of terminal ileitis: side-to-side enterocolic anastomosis.  Dis Colon Rectum. 1997;  40 234-237 (III)
    Google Scholar
  • 18 Cosnes J, Carbonnel F, Carrat F. et al . Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study.  Gut. 1999;  45 218-222 (III)
    Google Scholar
  • 19 Fazio V W, Marchetti F, Church M. et al . Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial.  Ann Surg. 1996;  224 563-571 (Ib)
    Google Scholar
  • 20 Malchow H, Ewe K, Brandes J el al. European cooperative Crohn’s disease study (ECCDS): results of drug treatment.  Gastroenterology. 1984;  86 249-266 (Ib)
    Google Scholar
  • 21 Wyatt J, Vogelsang H, Hubl W. et al . Intestinal permeability and the prediction of relapse in Crohn’s disease.  Lancet. 1993;  341 1437-1439 (III)
    Google Scholar
  • 22 Peeters M, Geypens B, Claus D. et al . Clustering of increased small intestinal permeability in families with Crohn’s disease.  Gastroenterology. 1997;  113 802-807 (IIb)
    Google Scholar
  • 23 Tibble J A, Sigthorsson G, Bridger S. et al . Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.  Gastroenterology. 2000;  119 15-22 (III)
    Google Scholar
  • 24 Schreiber S, Nikolaus S, Hampe J. et al . Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn’s disease.  Lancet. 1999;  353 459-461 (III)
    Google Scholar
  • 25 Nikolaus S, Raedler A, Kuhbacker T. et al . Mechanisms in failure of infliximab for Crohn’s disease.  Lancet. 2000;  356 1475-1479 (III)
    Google Scholar
  • 26 Meresse B, Rutgeerts P, Malchow H. et al . Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn’s disease.  Gut. 2002;  50 25-28 (III)
    Google Scholar
  • 27 Parsi M A, Achkar J P, Richardson S. et al . Predictors of response to infliximab in patients with Crohn’s disease.  Gastroenterology. 2002;  123 707-713 (III)
    Google Scholar
  • 28 Pearson D C, May G R, Fick G H. et al . Azathioprine and 6-mercaptopurine in Crohn’s disease. A metaanalysis.  Ann Intern Med. 1995;  123 132-142 (Ia)
    Google Scholar
  • 29 Bouhnik Y, Lemann M, Mary J C. et al . Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine.  Lancet. 1996;  347 215-219 (Ib)
    Google Scholar
  • 30 Feagan B G, Rochon J, Fedorak N. et al . Methotrexate for the treatment of Crohn’s disease.  New Engl J Med. 1995;  332 292-297 (Ib)
    Google Scholar
  • 31 Rutgeerts P, D’Haens G, Targan S. et al . Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease.  Gastroenterology. 1999;  117 761-769 (Ib)
    Google Scholar
  • 32 Hanauer S B, Feagan B G, Lichtenstein G R. et al . Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial.  Lancet. 2002;  359 1541-1549 (Ib)
    Google Scholar
  • 33 Stange E F, Schreiber S, Raedler A. et al . Therapie des Morbus Crohn.  Z Gastroenterol. 1997;  35 541-554
    Google Scholar
  • 34 Messori A, Brignola C, Trallori G. et al . Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: A metaanalysis.  Am J Gastroenterol. 1994;  89 692-698 (Ia)
    Google Scholar
  • 35 Cammà C, Giunta M, Rosselli M. et al . Mesalamine in the treatment of Crohn’s disease-meta-analysis adjusted for confounding variables.  Gastroenterology. 1997;  113 1465-1473 (Ia)
    Google Scholar
  • 36 Papi C, Luchetti R, Gili L. et al . Budesonide in the treatment of Crohn’s disease: a meta-analysis.  Aliment Pharmacol Ther. 2000;  14 1419-1428 (Ia)
    Google Scholar
  • 37 Thomas G A, Swift G L, Green J T. et al . Controlled trial of antituberculous chemotherapy in Crohn’s disease: a five year follow up study.  Gut. 1998;  42 497-500 (Ib)
    Google Scholar
  • 38 Borgaonkar M R, MacIntosh D G, Fardy J M. A meta-analysis of antimycobacterial therapy for Crohn’s disease.  Am J Gastroenterol. 2000;  95 725-729 (Ia)
    Google Scholar
  • 39 Feagan B G, McDonald J W, Rochon J. et al . Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators.  N Engl J Med. 1994;  330 1846-1851 (Ib)
    Google Scholar
  • 40 Stange E F, Modigliani R, Pena S. et al . European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study. The European Study Group.  Gastroenterology. 1995;  109 774-782 (Ib)
    Google Scholar
  • 41 Fellermann K, Steffen M, Stein J. et al . Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease.  Aliment Pharmacol Ther. 2000;  14 171-176 (III)
    Google Scholar
  • 42 Malchow H A. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease?.  J Clin Gastroenterol. 1997;  25 653-658 (III)
    Google Scholar
  • 43 Belluzzi A, Brignola C, Campieri M. et al . Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease.  N Engl J Med. 1996;  334 1557-1560 (Ib)
    Google Scholar
  • 44 Lorenz-Meyer H, Bauer P, Nicolay C. et al . Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn’s disease. A randomized controlled multicenter trial. Study Group Members (German Crohn’s Disease Study Group).  Scand J Gastroenterol. 1996;  31 778-785 (Ib)
    Google Scholar
  • 45 Lochs H, Mayer M, Fleig W E. et al . Prophylaxis of postoperative relapse in Crohn’s disease with Pentasa, Results of the European CrohnŽs disease Study VI.  Gastroenterology. 2000;  118 264-273 (Ib)
    Google Scholar
  • 46 Cottone M, Cammà C. Mesalamine and relapse prevention in Crohn’s disease (Letter).  Gastroenterology. 2000;  118 597 (Ia)
    Google Scholar
  • 47 Mc L eod RS, Wolff B G, Steinhardt A H. et al . Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease.  Gastroenterology. 1995;  109 404-413 (Ib)
    Google Scholar
  • 48 Rutgeerts P, Hiele M, Geboes K. et al . Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection.  Gastroenterology. 1995;  108 1617-1621 (Ib)
    Google Scholar
  • 49 Smith R C, Rhodes J, Heatley R V. et al . Low dose steroids and clinical relapse in Crohn’s disease: a controlled trial.  Gut. 1978;  19 606-610 (Ib)
    Google Scholar
  • 50 Ewe K, Böttger T, Buhr H J. et al . Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial.  Eur J Gastroenterol Hepatol. 1999;  11 277-282 (Ib)
    Google Scholar
  • 51 Hellers G, Cortot A, Jewell D. et al . Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease.  Gastroenterology. 1999;  116 294-300 (Ib)
    Google Scholar
  • 52 Colombel J F, Rutgeerts P, Malchow H. et al . Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease.  Gut. 2001;  49 42-46 (Ib)
    Google Scholar
  • 53 Prantera C, Scribano M L, Falasco G. et al . Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG.  Gut. 2002;  51 405-409 (Ib)
    Google Scholar
  • 54 Markowitz J, Grancher K, Kohn N. et al . A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease.  Gastroenterology. 2000;  119 895-902 (Ib)
    Google Scholar
  • 55 Vogelsang H, Granditsch G, Binder C. et al . Consensus of the Chronic Inflammatory Bowl Disease Study Group of the Austrian Society of Gastroenterology and Hepatology on the topic of „diagnosis and therapy of chronic inflammatory bowel diseases in adolescence”.  Z Gastroenterol. 2000;  38 791-794
    Google Scholar
  • 56 Mogadam M, Korelitz B I, Ahmed S W. et al . The course of inflammatory bowel disease during pregnancy and postpartum.  Am J Gastroenterol. 1981;  75 265-269 (III)
    Google Scholar
  • 57 Habal F M, Hui G, Greenberg G R. Oral 5-aminosalicylic acid for imflammatory bowel disease in pregnancy: safety and clinical course.  Gastroenterology. 1993;  105 1057-1062 (III)
    Google Scholar
  • 58 Alstead E M, Ritchie J K, Lennard-Jones J E. et al . Safety of azathioprin in pregnancy in inflammatory bowel disease.  Gastroenterology. 1990;  97 443-446 (III)
    Google Scholar
  • 59 Present D H, Meltzer S J, Krumholz M P. et al . 6-Mercaptopurine in the management of inflammatory bowel disease.  Am Col Phys. 1989;  111 641-649 (III)
    Google Scholar
  • 60 Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn’s disease.  Am J Gastroenterol. 2001;  96 2274-2275
    Google Scholar